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Reaching an ACCORD on Glycemia and Systolic Blood Pressure
Targets in Type 2 Diabetes Mellitus
Thomas M. MacDonald, FRCPE; Isla S. Mackenzie, FRCPE
P atients with type 2 diabetes mellitus experiencemicrovascular and macrovascular complications from
their condition. Microvascular complications include renal,
retinal, and neuropathic disease. Macrovascular complica-
tions include coronary, cerebrovascular, and peripheral arte-
rial diseases that lead to premature cardiovascular death.
These complications are competing risks. Dying at a young
age from macrovascular disease means that some subjects
with diabetes mellitus do not have the opportunity to develop
advanced microvascular disease.
Studies of diabetes mellitus medications that have reduced
cardiovascular events have previously used single-agent
interventions that have resulted in only modest reductions
in glucose control (usually with a glycated hemoglobin still
>7.0%), and the beneﬁcial effects may have been medication
rather than glucose-control related. Thus, the UKPDS (UK
Prospective Diabetes Study) found a reduction in cardiovas-
cular events with metformin in a study of overweight newly
diagnosed patients free from symptoms on a diet and
followed up for 11 years, with a reduction in glycated
hemoglobin from 8.0% to 7.4%.1 A trial of liraglutide, a
glucagon-like peptide-1 receptor agonist, decreased glycated
hemoglobin by 0.4% from 8.7% and systolic blood pressure
(SBP) by 1.2 mm Hg and reduced cardiovascular events
signiﬁcantly.2 However, another glucagon-like peptide-1
receptor agonist that reduced glycated hemoglobin by
between 0.7% and 1% (depending on randomized dose) from
a baseline of 8.7%, and also lowered SBP by 1.3 to
2.6 mm Hg, decreased nonfatal but not fatal cardiovascular
events while actually increasing retinopathy.3 More recently,
treatment with sodium-glucose cotransporter-2 inhibitors (eg,
empagliﬂozin) had reduced glycated hemoglobin by 0.5% to
0.6% (depending on the dose used) from a baseline of 8.1%
and mainly reduced cardiovascular death and heart failure
(possibly at least in part by lowering SBP by 4 mm Hg).4
All of these trials of diabetes mellitus medications
decreased glycated hemoglobin modestly and cannot really
be used to compare “tight” glycemic control with standard
glycemic control.
To date, tight glycemic control versus standard control has
not been shown to prevent macrovascular disease but has led
to reductions in microvascular complications.5 Managing
traditional cardiovascular risk factors, such as lowering blood
pressure, treating dyslipidemia, and increasing exercise and
smoking cessation, unquestionably reduces macrovascular
disease and leads to prolonged survival.
The ACCORD BP (Action to Control Cardiovascular Risk in
Diabetes Blood Pressure) study was a 292 factorial design
study that tested intensive (<120 mm Hg) versus standard
(<140 mm Hg) SBP control and intensive (<6% glycated
hemoglobin) versus standard (7.0%–7.9% glycated hemoglo-
bin) glycemic control in subjects with type 2 diabetes
mellitus.6 The trial results caused some consternation, with
intensive glucose control increasing mortality and intensive
SBP control having no signiﬁcant effect.
The article by Beddhu and others in this issue of the
Journal of the American Heart Association (JAHA) casts light
on the blood pressure aspect of the ACCORD BP study.7
The authors have investigated why the ACCORD BP study
blood pressure results were different from those of the
SPRINT (Systolic Blood Pressure Intervention Trial), which
showed beneﬁts of the same lower SBP target of
120 mm Hg versus 140 mm Hg in subjects who did not
have diabetes mellitus.
SPRINT reported a reduction in the composite primary
cardiovascular outcome of time to the ﬁrst event of
nonfatal myocardial infarction, acute coronary syndrome
not resulting in myocardial infarction, nonfatal stroke,
acute decompensated heart failure, or death from cardio-
vascular disease causes.8 A signiﬁcant reduction in this
composite primary end point was found and was driven to
a large part by fewer cardiovascular deaths and fewer
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cases of decompensated heart failure. The ACCORD BP
study primary end point was similar to the SPRINT
composite end point but excluded acute coronary syn-
drome and decompensated heart failure. To better com-
pare the 2 trials, Beddhu et al7 deﬁned a modiﬁed
ACCORD BP study end point by adding to the primary
outcome congestive heart failure and unstable angina
events that occurred (which presumably closely resemble
acute decompensated heart failure and acute coronary
syndrome reported in SPRINT). They then compared the
ACCORD BP study modiﬁed primary end points in those
subjects randomized to the standard glycemic control and
intensive glycemic control arms of the ACCORD BP study.
There were some other differences between the ACCORD
BP study and SPRINT. The ACCORD BP study was a much
smaller study and the demographics differed, with ACCORD
BP study subjects being younger, being more often women,
and having a higher body mass index among other things.
However, BP lowering was similar.
The most interesting ﬁnding of this post hoc analysis was
that SBP lowering in the ACCORD BP study decreased the
hazard of the composite end point or mortality in the ACCORD
BP study similarly to SPRINT in the standard glycemic control
arm but not in the intensive glycemic control arm.
The mechanism of why the double intervention of intensive
SBP and intensive glycemic control was so different from
intensive SBP and standard glycemic control will be the
subject of speculation and debate. It seems that lowering SBP
to 120 mm Hg in patients with type 2 diabetes mellitus is
beneﬁcial in preventing macrovascular disease as long as one
does not also strive for intensive glucose control.
The overall message for physicians treating patients with
type 2 diabetes mellitus is that tight glucose control should be
avoided and instead clinicians should focus their skills at
reducing SBP, cholesterol, and smoking while encouraging
weight loss and regular exercise, a message that has been
wisely stated by others.9
It is not a good outcome for patients with diabetes mellitus
to die early with good eyesight or reduced proteinuria.
Avoiding tight glycemic control allows patients with diabetes
mellitus to reap the considerable beneﬁts of an SBP target of
≤120 mm Hg.
It is time to change practice.
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